DEFEROXAMINE MESYLATE (cas 138-14-7) enhances virulence of community-associated methicillin resistant Staphylococcus aureus

Add time:09/29/2019    Source:infona.pl

Staphylococcus aureus is a leading cause of bacterial infections. Strains of community-associated methicillin-resistant S. aureus (CA-MRSA), such as USA300, display enhanced virulence and fitness. Patients suffering from iron overload diseases often undergo iron chelation therapy with DEFEROXAMINE MESYLATE (cas 138-14-7) (DFO). Here, we show that USA300 uses this drug to acquire iron. We further demonstrate that mice administered DFO I.P., versus those not administered DFO, had significantly higher bacterial burden in livers and kidneys after I.V. challenge with USA300, associated with increased abscess formation and tissue destruction. The virulence of USA300 mutants defective for DFO uptake was not affected by DFO treatment.

We also recommend Trading Suppliers and Manufacturers of DEFEROXAMINE MESYLATE (cas 138-14-7). Pls Click Website Link as below: cas 138-14-7 suppliers

Prev:The Effects of DEFEROXAMINE MESYLATE (cas 138-14-7) on Iron Elimination after Blood Transfusion in Neonatal Foals
Next:Treatment with the Iron Chelator, DEFEROXAMINE MESYLATE (cas 138-14-7), Alters Serum Markers of Oxidative Stress in Stroke Patients)